IMC Chicago’s Vertex Pharmaceuticals VRTX Stock Holding History

IMC Chicago’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,533	Closed	-$2.01M	–	6846
2026 Q1	$2.02M	Buy	+4,533	New	+$2.11M	﹤0.01%	2555

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

IMC Chicago's VRTX Position: Q2 2026 in Review

IMC Chicago sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 4,533 shares — an estimated $2.01M sold.

IMC Chicago first reported a position in VRTX in Q1 2026 and held it in 1 quarter. The position peaked at $2.02M in Q1 2026. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

IMC Chicago reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 4,533 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
IMC Chicago first reported a position in Vertex Pharmaceuticals in Q1 2026 and held it in 1 quarter.
IMC Chicago's Vertex Pharmaceuticals position peaked at $2.02M in Q1 2026.
1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.